Correction: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

1. These authors contributed equally: Shu Lin, Lifeng Yu

Authors and Affiliations

1. Department of Pharmacology, School of Pharmacy, China Medical University, No. 77 Puhe Road, Shenyang North New Area, 110122, Shenyang City, Liaoning, China

   Shu Lin, Lifeng Yu, Xinyue Song, Jia Bi, Longyang Jiang, Yan Wang, Miao He, Qinghuan Xiao, Mingli Sun, Lin Zhao & Minjie Wei

2. Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation, China Medical University, No.77 Puhe Road, Shenyang North New Area, 110122, Shenyang City, Liaoning, China

   Shu Lin, Lifeng Yu, Xinyue Song, Jia Bi, Longyang Jiang, Yan Wang, Miao He, Qinghuan Xiao, Mingli Sun & Lin Zhao

3. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637-1463, USA

   Olufunmilayo I. Olopade

Corresponding authors

Correspondence to Lin Zhao or Minjie Wei.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions